SCHNELL DAVID 4

4 · NGM BIOPHARMACEUTICALS INC · Filed Apr 10, 2019

Form 4

Period: 2019-04-08

Director

Transactions

Conversion
Series A Preferred Stock
2019-04-08−3,000,000→ 0 total(indirect: See Footnotes)
→ Common Stock (3,000,000 underlying)
Conversion
Series C Preferred Stock
2019-04-08−525,000→ 0 total(indirect: See Footnotes)
→ Common Stock (525,000 underlying)
Conversion
Series D Preferred Stock
2019-04-08−100,000→ 0 total(indirect: See Footnotes)
→ Common Stock (100,000 underlying)
Conversion
Common Stock
2019-04-08+4,925,000→ 4,925,000 total(indirect: See Footnotes)
Conversion
Series B Preferred Stock
2019-04-08−1,300,000→ 0 total(indirect: See Footnotes)
→ Common Stock (1,300,000 underlying)

Footnotes (7)

[F1]Every two shares of Series A preferred stock, Series B preferred stock, Series C preferred stock and Series D preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.
[F2]Consists of 4,925,000 shares beneficially owned by Prospect Ventures Partners III, L.P.
[F3]The Reporting Person, a Director of the Issuer, shares voting and dispositive power with the managing members of Prospect Management Co. III, L.L.C., which is the general partner of Prospect Ventures Partners III, L.P., but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
[F4]Consists of 3,000,000 shares beneficially owned by Prospect Ventures Partners III, L.P.
[F5]Consists of 1,300,000 shares beneficially owned by Prospect Ventures Partners III, L.P.
[F6]Consists of 525,000 shares beneficially owned by Prospect Ventures Partners III, L.P.
[F7]Consists of 100,000 shares beneficially owned by Prospect Ventures Partners III, L.P.

Documents

1 file